Difference to be detected | Difference to be detected expressed as odds ratio | |||
---|---|---|---|---|
Factors tested | Mean gain in pain controla, % (95 % CI) | P-value | Mean odds ratio (95 % CI) | P-value |
Baseline risk | <0.001 | 0.017 | ||
Low risk (90 % of controlled pain) (n = 186) High risk (50 % of controlled pain) (n = 184) | 6.0 (4.9–7.1) 16.0 (14.9–17.1) | 2.3 (2.1–2.5) 2.0 (1.9–2.2) | ||
Study population | 0.065 | 0.082 | ||
Adults (n = 188) Children (n = 182) | 10.3 (9.2–11.3) 11.7 (10.6–12.8) | 2.1 (1.9–2.2) 2.3 (2.1–2.4) | ||
Difficulties to recruit patients in the trial | 0.111 | 0.029 | ||
No difficulty to recruit patients (n = 183) Difficulties to recruit patients (n = 187) | 10.3 (9.3–11.4) 11.6 (10.5–12.7) | 2.0 (1.9–2.2) 2.3 (2.1–2.5) | ||
Disadvantages of the new treatment | 0.135 | 0.123 | ||
Risk of minor digestive side effects (n = 183) Risk of severe allergic reactions (n = 187) | 10.4 (9.3–11.5) 11.6 (10.5–12.6) | 2.1 (1.9–2.2) 2.2 (2.1–2.4) |